FORMYCON AG - DE000A1EWVY8 (Stock)
Hannover
Price | Diff.% | Date & Time | Bid volume | Bid | Ask | Ask volume |
---|---|---|---|---|---|---|
23,00 EUR
![]() |
-0,2169% | 16.05.2025 08:26 | - | - | - | - |
Contact | |
---|---|
Formycon AG Fraunhoferstraße 15, Martinsried, Planegg 82152, München, DE |
|
Phone | +49-89-864667-100 |
Fax | +49-89-864667-110 |
info@formycon.com | |
Internet | http://formycon.com |
IR Contact/PR Contact | -/- |
Symbol | |
End of financial year | 31.12.2025 |
Issued capital | 404.514.760,00 EUR |
Shareholders | |
---|---|
Freefloat | 36,21% |
Struengmann Family | 24,24% |
Wendeln & Cie. KG | 13,54% |
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt. | 9,08% |
Active Ownership Corp SARL | 6,08% |
DSP Beteiligungsgesellschaft mbH & Co. KG | 4,99% |
Stefan Reichensperger | 3,28% |
Norges Bank Investment Management | 0,91% |
ACATIS Investment Kapitalverwaltungsgesellschaft mbH | 0,75% |
Plutos Vermögensverwaltung AG | 0,57% |
Lupus alpha Asset Management AG | 0,35% |
Board | |
---|---|
Dr. Stefan Glombitza | Chairman of Managing Board |
Nicola Mikulcik | Member of Executive Committee |
Enno Spillner | Member of Executive Committee |
Andreas Seidl | Member of Executive Committee |
Wolfgang Essler | Chairman of Supervisory Board |
Klaus Röhrig | Member of Supervisory Board |
Colin Michael Bond | Member of Supervisory Board |
Dr. Bodo Coldewey | Member of Supervisory Board |
Nicholas Haggar | Member of Supervisory Board |
Activity Description |
---|
Formycon AG engages in the manufacture of biosimilar drugs and formulations. Its product candidates include FYB201, FYB202, FYB203, and FYB205, which focuses in the opthalmology and immunology disease areas. The company was founded by Friedrich Wilhelm Steinweg and Nicolas Combé in 2007 and is headquartered in Munich, Germany. |